Natus Medical (NASDAQ:NTUS) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research downgraded shares of Natus Medical (NASDAQ:NTUS) from a buy rating to a hold rating in a research note released on Friday morning, reports.

According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “

NTUS traded down $0.14 during trading hours on Friday, reaching $31.74. 164,400 shares of the stock traded hands, compared to its average volume of 241,076. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of 22.35 and a beta of 0.63. Natus Medical has a fifty-two week low of $22.25 and a fifty-two week high of $37.90. The company has a current ratio of 1.93, a quick ratio of 1.36 and a debt-to-equity ratio of 0.15.

Natus Medical (NASDAQ:NTUS) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.34 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.04. The business had revenue of $125.54 million during the quarter, compared to analyst estimates of $122.85 million. Natus Medical had a negative net margin of 7.38% and a positive return on equity of 10.73%. On average, analysts forecast that Natus Medical will post 1.27 earnings per share for the current fiscal year.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Article: Can systematic risk be avoided?

Get a free copy of the Zacks research report on Natus Medical (NTUS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with's FREE daily email newsletter.